Singapore markets open in 2 hours 31 minutes

Kadmon Holdings, Inc. (KDMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.84+0.01 (+0.11%)
At close: 4:00PM EDT
8.83 -0.01 (-0.11%)
After hours: 06:07PM EDT

Kadmon Holdings, Inc.

450 East 29th Street
New York, NY 10016
United States
833 900 5366

Full-time employees127

Key executives

NameTitlePayExercisedYear born
Dr. Harlan W. WaksalPres, CEO & Director1.22MN/A1953
Mr. Steven MeehanExec. VP & CFO830kN/A1965
Mr. Gregory S. Moss Esq.Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer709.88kN/A1984
Mr. Kyle CarverSr. VP, Chief Accounting Officer & ControllerN/AN/AN/A
Ellen CavaleriDirector of Investor RelationsN/AN/AN/A
Dr. John L. Ryan M.D., Ph.D.Exec. VP and Exec. Medical Director of Clinical & Regulatory Devel.N/AN/A1943
Mr. Sanjay AggarwalSr. VP of Clinical Devel.N/AN/AN/A
Ms. Haya Taitel M.S., R.Ph.Sr. VP & Chief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.

Corporate governance

Kadmon Holdings, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.